As one of the top 10 oncology companies in the world, Lilly Oncology focuses on speeding innovation and improving outcomes for individual patients, and boast one of the largest clinical pipelines in the oncology industry. For more than four decades, Lilly has been dedicated to delivering innovative solutions that accelerate the pace and progress of cancer care and enhance the lives of people living with cancer.
What Makes Lilly Unique
Today, Lilly Oncology has one of the most robust clinical stage pipelines in the industry. Included in our pipeline are both small molecules and biologics, which are being studied to treat a wide range of cancers. For nearly all molecules in our pipeline, we have biomarker strategies targeting a genetic defect or genetic overexpression. These biomarkers help identify patients who have a higher likelihood of responding to treatment.
Today, Lilly Oncology continues to place a priority on speeding innovation that will improve outcomes for people facing cancer. Because no two people living with cancer are alike, we are committed to developing novel treatment approaches. Our strategy is focused on delivering “tailored therapies” as one of the key ways to speed innovation and improve outcomes for individual people. In doing so, we are finding ways to identify patients who are most likely to respond to therapy and just as importantly, which patients will not.
For any further specific healthcare related enquiries, please consult your healthcare professional.